Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Opinion|Videos|July 29, 2024
Targeting Disease Modification in Psoriasis and Psoriatic Arthritis
Listen
0:00 / 0:00
Dermatologic experts explore strategies to slow the progression of psoriasis to psoriatic arthritis, offering evidence-based insights to optimize patient outcomes and enhance long-term disease management.
Advertisement
0:00 Overlap of PsO and PsA
4:00 Detecting Early PsA
13:20 Treatments for PsA
18:00 Defining Minimal Disease Activity
24:50 Biologics for PsA
31:00 Efficacy of IL-17i and IL-23i
37:00 Preventing Progression from PsO to PsA
Advertisement
Related to this article
Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for PsA.
In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.
Ruderman discusses how Northwestern's joint dermatology-rheumatology clinic shapes diagnosis and treatment of psoriatic disease.
Sonelokimab hit its primary ACR50 endpoint and all key secondary endpoints in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial.
Mease revisits the biggest PsA readouts from EULAR 2026: guselkumab, izokibep, GLP-1 combo therapy and more.
Advertisement
Advertisement